• Medientyp: E-Artikel
  • Titel: DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
  • Beteiligte: Sormani, Maria Pia; Salvetti, Marco; Labauge, Pierre; Schiavetti, Irene; Zephir, Helene; Carmisciano, Luca; Bensa, Caroline; De Rossi, Nicola; Pelletier, Jean; Cordioli, Cinzia; Vukusic, Sandra; Moiola, Lucia; Kerschen, Philippe; Radaelli, Marta; Théaudin, Marie; Immovilli, Paolo; Casez, Olivier; Capobianco, Marco; Ciron, Jonathan; Trojano, Maria; Stankoff, Bruno; Créange, Alain; Tedeschi, Gioacchino; Clavelou, Pierre; [...]
  • Erschienen: Wiley, 2021
  • Erschienen in: Annals of Clinical and Translational Neurology
  • Umfang: 1738-1744
  • Sprache: Englisch
  • DOI: 10.1002/acn3.51408
  • ISSN: 2328-9503
  • Schlagwörter: Neurology (clinical) ; General Neuroscience
  • Zusammenfassung: <jats:title>Abstract</jats:title><jats:p>We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect meta‐analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti‐CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, <jats:italic>p</jats:italic> &lt; 0.001) with Covid‐19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, <jats:italic>p</jats:italic> = 0.047). This pooled‐analysis confirms an increased risk of severe Covid‐19 in patients on anti‐CD20 therapies and supports the protective role of interferon.</jats:p>
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect meta‐analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti‐CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, <jats:italic>p</jats:italic> &lt; 0.001) with Covid‐19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, <jats:italic>p</jats:italic> = 0.047). This pooled‐analysis confirms an increased risk of severe Covid‐19 in patients on anti‐CD20 therapies and supports the protective role of interferon.</jats:p>
  • Anmerkungen:
  • Zugangsstatus: Freier Zugang